Josh Callahan PhD, Research Assistant Professor, Bevan Lab, Department of Neuroscience
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by a trinucleotide CAG repeat expansion in the huntingtin gene (HTT). The debilitating psychomotor symptoms of HD are linked to basal ganglia indirect pathway degeneration. The glutamatergic subthalamic nucleus (STN) is a key component of this pathway and a primary site of dysregulation. In symptomatic 6-12-month-old Q175 HDmice, STN neurons exhibit: (1) NMDA receptor-dependent mitochondrial oxidant stress, (2) reactive oxygen species-mediated KATP channel activation, (3) transcriptional dysregulation, (4) ex vivo autonomous firing loss and in vivo hypoactivity. This pathophysiology is selective for motor cortical-recipient, pro-motor STN neurons (type 1), which increase their activity during locomotion and in control mice optimize movement. Although neuron loss is typically negligible in HD mice, 25% of STN neurons die by 18-months in Q175 mice, mirroring human pathology. Together, these findings establish the STN as a key site for the development and application of symptomatic and disease-modifying treatments in HD.
Zinc finger protein transcriptional repressors (ZFPs) that target expanded CAG repeats can selectively reduce mutant huntingtin (mHTT) expression. To evaluate their efficacy in the STN, AAV-encoding ZFPs were injected bilaterally in the STN of Q175 mice before (2 months) or after (6 months) the onset of pathophysiology. Late ZFP treatment: (1) reduced STN mitochondrial oxidant stress and restored autonomous firing, (2) rescued type 1 STN activity in vivo, (3) improved locomotion performance and kinematics. However, this late intervention did not prevent STN neuron loss. In contrast, early ZFP treatment improved locomotion and prevented STN cell loss. Together, these data demonstrate that mHTT suppression can reverse pathophysiology in symptomatic mice and prevent cell death when treatment is initiated prior to symptom onset. Our findings support further development and application of ZFPs for HD treatment and highlight the importance of ZFP timing and target selection.
Audience
- Faculty/Staff
- Student
- Post Docs/Docs
- Graduate Students
Contact
Angela Mohr
Email
Interest
- Academic (general)